Acrivon has developed its AP3 Interactome, a proprietary, computational analytics platform driven by Generative ...

Wojciech Jurczak, MD, PhD, discusses advancements in B-cell lymphoma therapy, focusing on immunotherapy, molecular-targeted agents, and more.

The data to be presented encompasses five of the company’s novel drug candidates: BCR-ABL tyrosine kinase inhibitor olverembatinib (HQP1351), Bcl-2 inhibitor lisaftoclax (APG-2575), FAK/ALK/ROS1 ...

Evolution in women's cancer diagnostics: from histopathology to molecular testing, personalized treatment for breast, ovarian ...

an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through ...

In this video, John O. Mascarenhas, MD, professor of medicine at the Icahn School of Medicine, discussed recent developments and emerging treatments in myeloproliferative neoplasms care.

A novel two-drug combination exhibited antitumor activity among certain women with advanced endometrial cancer, data ...

This marks Jacobio's successful transformation from the early R&D stage to an innovation-driven value realization stage," said Dr.Yinxiang Wang, the Chairman and CEO of Jacobio Pharma. "Looking ahead ...

Researchers at the Garvan Institute of Medical Research have uncovered how pancreatic cancer hijacks a crucial metabolic ...